Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Depreciation & Amortization (CF) (2019 - 2022)

Cyclerion Therapeutics has reported Depreciation & Amortization (CF) over the past 4 years, most recently at $100000.0 for Q3 2022.

  • Quarterly results put Depreciation & Amortization (CF) at $100000.0 for Q3 2022, down 83.33% from a year ago — trailing twelve months through Jun 2023 was $100000.0 (down 87.44% YoY), and the annual figure for FY2022 was $65000.0, down 86.23%.
  • Depreciation & Amortization (CF) for Q3 2022 was $100000.0 at Cyclerion Therapeutics, roughly flat from $100000.0 in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for CYCN hit a ceiling of $800000.0 in Q2 2019 and a floor of $48000.0 in Q4 2021.
  • Median Depreciation & Amortization (CF) over the past 4 years was $525000.0 (2019), compared with a mean of $415200.0.
  • Biggest five-year swings in Depreciation & Amortization (CF): rose 19.24% in 2020 and later tumbled 89.79% in 2021.
  • Cyclerion Therapeutics' Depreciation & Amortization (CF) stood at $653000.0 in 2019, then fell by 28.02% to $470000.0 in 2020, then tumbled by 89.79% to $48000.0 in 2021, then soared by 108.33% to $100000.0 in 2022.
  • The last three reported values for Depreciation & Amortization (CF) were $100000.0 (Q3 2022), $100000.0 (Q2 2022), and $48000.0 (Q1 2022) per Business Quant data.